A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.

2024-512954-96-00 Protocol CAN-201 NDG Phase I and Phase II (Integrated) - Other Ended

Start 14 May 2024 · End 30 Apr 2026 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol CAN-201 NDG

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 32
Countries 1
Sites 4

Glioblastoma

Key facts

Sponsor
Cantex Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 May 2024 → 30 Apr 2026
Decision date (initial)
2024-05-14
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512954-96-00
EudraCT number
2022-002801-36
ClinicalTrials.gov
NCT05635734

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cantex Pharmaceuticals Inc.

Sponsor organisation
Cantex Pharmaceuticals Inc.
Address
1792 Bell Tower Lane Suite 222
City
Weston
Postcode
33326-3682
Country
United States

Scientific contact point

Organisation
Cantex Pharmaceuticals Inc.
Contact name
A Person designated by the Sponsor

Public contact point

Organisation
Cantex Pharmaceuticals Inc.
Contact name
A Person designated by the Sponsor

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 32 4
Rest of world 0

Investigational sites

Spain

4 sites · Ended
Hospital Clinic De Barcelona
Onología Médica, Calle Villarroel 170, 08036, Barcelona
Hospital Del Mar
Oncología Médica, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Hospital Universitario 12 De Octubre
Medical Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Ramon Y Cajal
Oncología Médica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-05-14 2026-04-30 2024-05-14 2025-05-16

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-06 Spain Acceptable
2024-05-14
2024-05-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-11 Spain Acceptable
2024-11-11
2024-11-11